Anandaroop Dasgupta

Medicine · Health Sciences

8h-index221citations36works2.42yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Advanced Breast Cancer Therapies(7), HER2/EGFR in Cancer Research(6), Health Systems, Economic Evaluations, Quality of Life(6), Cancer Immunotherapy and Biomarkers(5), Lung Cancer Treatments and Mutations(5)

Publications36 total

Patient-reported outcome measures in recurrent/advanced endometrial cancer: A targeted literature review and clinician perspectives
International Journal of Gynecological Cancer·2026
HTA16 A Systematic Literature Review of the Mitigation Strategies to Overcome the Risk for Confounding of Overall Survival in Trials With Crossover/Treatment Switching Evaluated in Health Technology Assessments of Treatments for Select Tumors in Oncology
Value in Health·2025
REAL-WORLD TREATMENT PATTERNS AND OUTCOMES IN PATIENTS DIAGNOSED WITH ADVANCED ENDOMETRIAL CANCER TREATED WITH IMMUNO-ONCOLOGY THERAPIES IN THE UNITED STATES: 2019-2024
International Journal of Gynecological Cancer·2025
A Review of the Utilization of Relative Dose Intensity and Dose Delay Factor in Health Technology Appraisals of Oncology Drugs in Solid Tumors
Advances in Therapy·2025
PCR258 Humanistic Burden in Metastatic Triple-Negative Breast Cancer (mTNBC): A Systematic Literature Review (SLR)
Value in Health·2025
HTA2 Role of Relative Dose Intensity in Health Economic Evaluations: A Review of National Institute for Health and Care Excellence Technology Appraisals of Treatments in Solid Tumors
Value in Health·2025
Q-TWiST Analysis to Assess Benefit-Risk of Sacituzumab Govitecan in Previously Treated Patients With Metastatic Triple-Negative Breast Cancer
JCO Oncology Practice·2025· 1 cited
Abstract P2-01-05: Quality-adjusted Time Without Symptoms of disease progression or Toxicity of treatment (Q-TWiST) Analysis of Sacituzumab Govitecan vs Chemotherapy in Previously Treated Patients with HR+/HER2– Metastatic Breast Cancer
Clinical Cancer Research·2025
Abstract P2-07-19: Health-Related Quality of Life with Sacituzumab Govitecan versus Treatment of Physician’s Choice in Previously Treated Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: A Meta-Analysis of TROPiCS-02 and EVER-132-002 Trials
Clinical Cancer Research·2025
A Meta-Analysis of Patient-Reported Outcomes of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Previously Treated HR+/HER− mBC Using Two Phase 3 (TROPiCS-02 and EVER-132-002) Trials
Cancers·2025Open Access
Q-TWiST Analysis of Sacituzumab Govitecan vs. Chemotherapy in Previously Treated Patients with HR+/HER2− Metastatic Breast Cancer
Current Oncology·2025· 2 citedOpen Access
Efficacy of sacituzumab govitecan versus treatment of physician’s choice in previously treated HR+ and HER2− mBC: a meta-analysis of TROPiCS-02 and EVER-132-002 trials
Therapeutic Advances in Medical Oncology·2025· 4 citedOpen Access
Sacituzumab govitecan in HR+HER2− metastatic breast cancer: the randomized phase 3 EVER-132-002 trial
Nature Medicine·2024· 29 citedOpen Access
Real-World Outcomes of First-Line Treatment With Anti–PD(L)1-Based Combination Therapy for Nonsquamous Metastatic Non–Small Cell Lung Cancer: A Multiregional Chart Review in Europe, Japan, and the United States
JCO Global Oncology·2024· 2 citedOpen Access
PP01.09 Real-world clinical outcomes after progression with anti-PD(L)1 and chemotherapy in mNSCLC in the US
Journal of Thoracic Oncology·2024Open Access
PP01.08 Real-world outcomes of first-line anti-PD(L)1-based combination therapy for mNSCLC in Europe
Journal of Thoracic Oncology·2024Open Access
Real-World Treatment Patterns and Clinical Outcomes After Platinum-Doublet Chemotherapy and Immunotherapy in Metastatic Non–Small Cell Lung Cancer: A Multiregional Chart Review in the United States, Europe, and Japan
JCO Global Oncology·2024· 3 citedOpen Access
791 Treatment patterns and real-world clinical outcomes of first-line anti-PD(L)1-based combination therapy among patients with non-squamous metastatic non-small cell lung cancer in Japan
Regular and Young Investigator Award Abstracts·2023Open Access
How well do clinical and demographic characteristics predict Patient Health Questionnaire‐9 scores among patients with treatment‐resistant major depressive disorder in a real‐world setting?
Brain and Behavior·2021· 7 citedOpen Access
Treatment Pattern and Outcomes in Newly Diagnosed Multiple Myeloma Patients Who Did Not Receive Autologous Stem Cell Transplantation: A Real-World Observational Study
Advances in Therapy·2020· 10 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Ankita Kaushik(9), Sujit S. Sansgiry(6), Hope S. Rugo(6), Joyce A. Tipton(5), Wendy Verret(5), Ticiana Leal(5), Dominick Latrémouille-Viau(5), Carmine Rossi(5), Pragya Rai(5), Fabrice Barlési(5), Stephen V. Liu(5), Nilanjana Dwibedi(4), Craig P. Frost(4), Barinder Singh(4), Sheeba M. Jacob(3), Kimberly M. Komatsubara(3), Samir Sikri(3), Binghe Xu(3), Aditya Bardia(3), Adam Brufsky(3)